Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. (Q44587971)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

title

Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

author name string

Yu Z Bagger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

László B Tankó

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Peter Alexandersen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Claus Christiansen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

301-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and pathogenesis of osteoporosis

16 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Bisphosphonate effects and the bone remodeling transient.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Clinical pharmacology of alendronate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

Bisphosphonates: preclinical aspects and use in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900112-1

7 January 2021

10.1016/S8756-3282(03)00112-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13678770%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference